Mn Services Vermogensbeheer B.V. lowered its position in shares of Elevance Health, Inc. (NYSE:ELV - Free Report) by 6.9% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 86,600 shares of the company's stock after selling 6,400 shares during the period. Mn Services Vermogensbeheer B.V.'s holdings in Elevance Health were worth $37,668,000 at the end of the most recent reporting period.
Several other institutional investors have also added to or reduced their stakes in ELV. Accredited Wealth Management LLC purchased a new stake in Elevance Health during the 4th quarter valued at $25,000. Flagship Wealth Advisors LLC bought a new stake in Elevance Health during the fourth quarter worth about $26,000. OFI Invest Asset Management purchased a new stake in shares of Elevance Health in the 4th quarter worth approximately $29,000. WealthTrak Capital Management LLC bought a new stake in Elevance Health during the 4th quarter valued at about $29,000. Finally, Lee Danner & Bass Inc. bought a new stake in Elevance Health during the 4th quarter valued at about $30,000. Hedge funds and other institutional investors own 89.24% of the company's stock.
Elevance Health Stock Performance
Shares of ELV traded down $1.73 on Friday, reaching $384.49. The company's stock had a trading volume of 958,480 shares, compared to its average volume of 1,558,216. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.45 and a quick ratio of 1.50. The stock has a market capitalization of $86.87 billion, a P/E ratio of 15.01, a PEG ratio of 1.18 and a beta of 0.60. The stock's 50 day simple moving average is $404.71 and its two-hundred day simple moving average is $400.17. Elevance Health, Inc. has a 12-month low of $357.45 and a 12-month high of $567.26.
Elevance Health (NYSE:ELV - Get Free Report) last posted its quarterly earnings data on Tuesday, April 22nd. The company reported $11.97 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $10.60 by $1.37. The company had revenue of $48.77 billion for the quarter, compared to the consensus estimate of $46.26 billion. Elevance Health had a net margin of 3.38% and a return on equity of 18.28%. Research analysts forecast that Elevance Health, Inc. will post 33.96 earnings per share for the current fiscal year.
Elevance Health Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Wednesday, June 25th. Shareholders of record on Tuesday, June 10th will be issued a dividend of $1.71 per share. This represents a $6.84 annualized dividend and a yield of 1.78%. The ex-dividend date is Tuesday, June 10th. Elevance Health's dividend payout ratio is currently 26.69%.
Insider Buying and Selling at Elevance Health
In other Elevance Health news, CFO Mark Kaye sold 4,588 shares of Elevance Health stock in a transaction that occurred on Thursday, April 24th. The shares were sold at an average price of $424.82, for a total transaction of $1,949,074.16. Following the transaction, the chief financial officer now owns 18,977 shares of the company's stock, valued at $8,061,809.14. The trade was a 19.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.29% of the company's stock.
Analyst Ratings Changes
A number of research firms have weighed in on ELV. Argus set a $465.00 price objective on shares of Elevance Health in a research note on Friday, April 25th. Robert W. Baird restated a "neutral" rating and set a $529.00 price objective (down from $625.00) on shares of Elevance Health in a research note on Tuesday, April 15th. Baird R W lowered shares of Elevance Health from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, April 15th. Truist Financial set a $500.00 price target on shares of Elevance Health and gave the stock a "buy" rating in a research note on Monday, June 9th. Finally, Barclays reduced their price target on shares of Elevance Health from $522.00 to $480.00 and set an "overweight" rating for the company in a research note on Monday, June 2nd. Four analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $498.87.
Check Out Our Latest Report on ELV
Elevance Health Company Profile
(
Free Report)
Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.
Featured Stories
Before you consider Elevance Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elevance Health wasn't on the list.
While Elevance Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
